Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Sirion Biotech GmbH. (10/28/15). "Press Release: Novelty at Upcoming Bio Europe in Munich. Sirion Biotech Announces High Production Yields with Toxic Antigens for Vaccine Production". Munich.

Organisations Organisation Sirion Biotech GmbH
  Group Sirion Biotech (Group)
  Organisation 2 University of Copenhagen
Products Product HEK 293 cell line
  Product 2 Ad19a vector
Person Person Thirion, Christian (Sirion Biotech 201106 Managing Director + Founder)

Progress made with novel breakthrough vaccines: new production cell lines cope with difficult to express toxic antigens

Very soon will there be novel breakthrough vaccines in the market. Associating vaccines with just prophylaxis is a thought of the past, increasingly, vaccines will demonstrate therapeutic effects specifically in the field of so far difficult to address tumor diseases (immune therapies).

A critical hurdle has in the past been making enough of the vaccine vector material. This is especially difficult if not impossible when critical antigens are toxic because they are of viral or bacterial origin as is the case for HIV envelope proteins and bacterial virulence factors. This occurs in the majority of cases.

In a 2-years development project SIRION Biotech applied genetic modification to widespread and inexpensive HEK293 cells and suppressed specific antigen production during the process. This novel cell line overcomes production issues related to all DNA-based viral vectors that are expressing toxic proteins during the process. The technology is generally applicable to the production of DNA-vector based vaccines and can be applied to common vaccine production cell lines.

SIRION Biotech collaborates with Prof. Peter Holst from University of Copenhagen and combines new antigens with his innovative invariant chain adjuvant technology for the benefit of novel cancer immune therapies. Basis of such co-development is SIRION's lead candidate Ad19a as novel adenovirus serotype with promising immune response-stimulating activity. Next step is to study tolerance and efficiency in primates.

Experts gathering for Bio Europe in Munich next week will discuss applications of this novelty.

About SIRION Biotech

SIRION Biotech started in Munich in 2007 with the idea of developing next generation viral vectors for research, gene therapy and vaccines. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 500 single projects with more than 150 academic and industrial partners.

Contact SIRION Biotech:

Dr. Christian Thirion
Am Klopferspitz 19
D-82152 Martinsried
Tel.: +49-89-700 961 99-15

Record changed: 2019-01-13


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Sirion Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top